Abstract:The druggable proteome refers to proteins that can bind to small molecules with appropriate chemical affinity, inducing a favorable clinical response. Predicting druggable proteins through screening and in silico modeling is imperative for drug design. To contribute to this field, we developed an accurate predictive classifier for druggable cancer-driving proteins using amino acid composition descriptors of protein sequences and 13 machine learning linear and non-linear classifiers. The optimal classifier was achieved with the support vector machine method, utilizing 200 tri-amino acid composition descriptors. The high performance of the model is evident from an area under the receiver operating characteristics (AUROC) of 0.975 ± 0.003 and an accuracy of 0.929 ± 0.006 (threefold cross-validation). The machine learning prediction model was enhanced with multi-omics approaches, including the target-disease evidence score, the shortest pathways to cancer hallmarks, structure-based ligandability assessment, unfavorable prognostic protein analysis, and the oncogenic variome. Additionally, we performed a drug repurposing analysis to identify drugs with the highest affinity capable of targeting the best predicted proteins. As a result, we identified 79 key druggable cancer-driving proteins with the highest ligandability, and 23 of them demonstrated unfavorable prognostic significance across 16 TCGA PanCancer types: CDKN2A, BCL10, ACVR1, CASP8, JAG1, TSC1, NBN, PREX2, PPP2R1A, DNM2, VAV1, ASXL1, TPR, HRAS, BUB1B, ATG7, MARK3, SETD2, CCNE1, MUTYH, CDKN2C, RB1, and SMARCA4. Moreover, we prioritized 11 clinically relevant drugs targeting these proteins. This strategy effectively predicts and prioritizes biomarkers, therapeutic targets, and drugs for in-depth studies in clinical trials. Scripts are available at https://github.com/muntisa/machine-learning-for-druggable-proteins.

Informatic challenges and advances in illuminating the druggable proteome

Methods to Profile the Macromolecular Targets of Small Compounds.

DrugProtAI: A guide to the future research of investigational target proteins

Unexplored Therapeutic Opportunities in the Human Genome

Drugging the entire human proteome: are we there yet?

Exploiting Chemical Probes for Identifying Drug Target Proteins

Structural biology and bioinformatics in drug design: opportunities and challenges for target identification and lead discovery

Proteomic methods for drug target discovery

Identifying targets for drug discovery using bioinformatics

Systematic computational strategies for identifying protein targets and lead discovery

Using Bioinformatics for Drug Target Identification from the Genome

Emerging Pharmacotherapeutic Strategies to Overcome Undruggable Proteins in Cancer

A Survey On The Computational Approaches To Identify Drug Targets In The Postgenomic Era

Exploration of Target Spaces in the Human Genome for Protein and Peptide Drugs

Analysis of protein features and machine learning algorithms for prediction of druggable proteins

Evolution of In Silico Strategies for Protein-Protein Interaction Drug Discovery

Chemical-Protein Interactome and Its Application in Off-Target Identification

Bench to bedside: The ambitious goal of transducing medicinal chemistry from the lab to the clinic

Recent advances in targeting the "undruggable" proteins: from drug discovery to clinical trials

Unraveling druggable cancer-driving proteins and targeted drugs using artificial intelligence and multi-omics analyses

Proteomics： a New Approach for Drug Discovery